Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Alerts
Advertising
Job board
Subscribe
Contact
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews ...
Review Series
Next-Generation Sequencing in Medicine (Upcoming)
New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
Immunometabolism (Jan 2022)
Circadian Rhythm (Oct 2021)
Gut-Brain Axis (Jul 2021)
Tumor Microenvironment (Mar 2021)
100th Anniversary of Insulin's Discovery (Jan 2021)
View all review series ...
Viewpoint
Collections
In-Press Preview
Commentaries
Concise Communication
Editorials
Viewpoint
Top read articles
Clinical Medicine
JCI This Month
Current issue
Past issues
What should define a SARS-CoV-2 “breakthrough” infection?
John S. Schieffelin, … , Elizabeth B. Norton, Jay K. Kolls
John S. Schieffelin, … , Elizabeth B. Norton, Jay K. Kolls
Published May 11, 2021
Citation Information:
J Clin Invest.
2021;
131(12)
:e151186.
https://doi.org/10.1172/JCI151186
.
View:
Text
|
PDF
Viewpoint
What should define a SARS-CoV-2 “breakthrough” infection?
Text
PDF
Abstract
Authors
John S. Schieffelin, Elizabeth B. Norton, Jay K. Kolls
×
Full Text PDF |
Download
(303.25 KB)
